Addissie Selamawit, Klingemann Hans
Nantkwest Inc., Culver City, CA 99232, USA.
Vet Sci. 2018 Dec 6;5(4):100. doi: 10.3390/vetsci5040100.
Infusions with immune cells, such as lymphocytes or natural killer (NK) cells, represent one of several modalities of immunotherapy. In human patients with advanced B-cell leukemia or lymphoma, infusions with chimeric antigen receptor (CAR) T-lymphocytes have shown promising responses. However, the scientific and clinical development of cell-based therapies for dogs, who get cancer of similar types as humans, is lagging behind. One reason is that immune cells and their functionality in dogs are less well characterized, largely due a lack of canine-specific reagents to detect surface markers, and specific cytokines to isolate and expand their immune cells. This review summarizes the current status of canine cancer immunotherapies, with focus on autologous and allogeneic T-lymphocytes, as well as NK cells, and discusses potential initiatives that would allow therapies with canine immune cells to "catch up" with the advances in humans.
输注免疫细胞，如淋巴细胞或自然杀伤（NK）细胞，是免疫疗法的几种方式之一。在患有晚期B细胞白血病或淋巴瘤的人类患者中，输注嵌合抗原受体（CAR）T淋巴细胞已显示出有希望的反应。然而，对于患有与人类相似类型癌症的犬类，基于细胞的疗法的科学和临床开发却滞后了。一个原因是犬类的免疫细胞及其功能特征尚不明确，这主要是由于缺乏用于检测表面标志物的犬特异性试剂，以及用于分离和扩增其免疫细胞的特异性细胞因子。本综述总结了犬类癌症免疫疗法的现状，重点关注自体和异体T淋巴细胞以及NK细胞，并讨论了一些潜在举措，以使犬类免疫细胞疗法能够“赶上”人类的进展。
